Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sincere CoTSE:7782 +0.21%77 ROE % is 2.46% as of Dec. 2025, which is 70% below its 10-year median of 8.29. GuruFocus rates TSE:7782 with a GF Score™ of 77/100 and a GF Value™ of 円689.09 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 799 Medical Devices & Instruments companies, Sincere Co ranks better than 70.09% on this metric.
ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Sincere Co's annualized net income for the quarter that ended in Dec. 2025 was 円69 Mil. Sincere Co's average Total Stockholders Equity over the quarter that ended in Dec. 2025 was 円2,802 Mil. Therefore, Sincere Co's annualized ROE % for the quarter that ended in Dec. 2025 was 2.46%.
The historical rank and industry rank for Sincere Co's ROE % or its related term are showing as below:
TSE:7782'
s ROE % Range Over the Past 10 Years
Min: 0.76 Med: 8.29 Max: 13.44
Current: 8.95
During the past 12 years, Sincere Co's highest ROE % was 13.44%. The lowest was 0.76%. And the median was 8.29%.
TSE:7782's ROE % is ranked better than 70.09% of 799
companies
in the Medical Devices & Instruments industry
Industry Median: 2.68
vs TSE:7782: 8.95
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Dec. 2025) net income data. The Revenue data used here is four times the quarterly (Dec. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Sincere Co ROE % Related Terms
Sincere Co ROE % Historical Data
* Premium members only.
The historical data trend for Sincere Co's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Sincere Co's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sincere Co ROE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sincere Co's ROE % distribution charts can be found below:
* The bar in red indicates where Sincere Co's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Dec. 2025) net income data.
ROE % is displayed in the 30-year financial page.
Sincere Co (TSE:7782) has a ROE % of 2.46% as of Dec. 2025. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Sincere Co and its competitors. This is 70% below median its historical median of 8.29. Over the past decade, Sincere Co's ROE % has ranged from 0.76 to 13.44. According to the industry distribution chart, Sincere Co ranks #239 out of 799 companies in the Medical Devices & Instruments industry, placing it in the top 29.9%.
Is Sincere Co's ROE % too high?
Sincere Co's current ROE % of 2.46% is 70% below median its 10-year median of 8.29. Over the past 10 years, this metric has ranged from a low of 0.76 to a high of 13.44. The Medical Devices & Instruments industry median ROE % is 2.68. Sincere Co's value of 2.46% is 8.2% below this industry median. Based on the distribution chart, Sincere Co ranks #239 out of 799 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Sincere Co has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sincere Co's ROE % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Sincere Co ranks #239 out of 799 companies for ROE %. This puts Sincere Co in the upper half of its industry. The industry median ROE % is 2.68. Sincere Co's value of 2.46% is 8.2% below this benchmark. Historically, Sincere Co's own ROE % has ranged from 0.76 to 13.44 over the past decade. While the company's 10-year median is 8.29 vs. the industry median of 2.68, Sincere Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Devices & Instruments company?
The median ROE % among Medical Devices & Instruments companies is 2.68, based on 799 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sincere Co's current ROE % of 2.46% is 8.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Sincere Co and its competitors. For the Medical Devices & Instruments industry, the median ROE % is 2.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sincere Co's current ROE % is 2.46%, which is 70% below median its own 10-year median of 8.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sincere Co stock overvalued right now?
Based on GuruFocus' analysis, Sincere Co (TSE:7782) is currently considered Significantly Undervalued. The stock's GF Value™ is 円689.09, compared to a current price of 円472.00 — trading 31.5% below its estimated fair value. The current ROE % is 2.46%, which is 70% below median its 10-year median of 8.29 and 8.2% below the Medical Devices & Instruments industry median of 2.68. Sincere Co's overall GF Score™ is 77/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Sincere Co (TSE:7782), the current ROE % is 2.46% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sincere Co (TSE:7782) Overvalued in 2026?
Based on GuruFocus' analysis, Sincere Co stock appears to be undervalued.
The current stock price of 円472.00 is trading 31.5% below its estimated GF Value™ of 円689.09.
GuruFocus considers Sincere Co to be Significantly Undervalued.
Key valuation signals for TSE:7782:
ROE %: 2.46% (70% below median its 10-year median of 8.29)
GF Value™: 円689.09 vs. price of 円472.00 (31.5% below fair value)
Industry Position: 8.2% below the Medical Devices & Instruments median (#239 of 799)
No single metric tells the full story. See the TSE:7782 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sincere Co Ltd is a Japanese firm engaged in the manufacturing and sale of contact lens.As a company that manufactures and sells contact lenses, which are high-regulated medical devices, it place the highest priority on product safety and quality control, while working closely with company's customers to develop a variety-of-products and sell them at affordable prices to please as many customers as possible. The company opperates domestically as well as internationally.
77GF Score
Get the complete analysis for TSE:7782
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:7782 has been successfully added to your 
